Advertisement
Research Article

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

  • Morris E Feldman,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Beth Apsel,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Aino Uotila,

    Affiliation: Department of Molecular Biology, University of Geneva, Switzerland

    X
  • Robbie Loewith,

    Affiliation: Department of Molecular Biology, University of Geneva, Switzerland

    X
  • Zachary A Knight,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    ยค Current address: The Rockefeller University, New York, New York, United States of America

    X
  • Davide Ruggero,

    Affiliation: School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States of America

    X
  • Kevan M Shokat mail

    To whom correspondence should be addressed. E-mail: shokat@cmp.ucsf.edu

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Published: February 10, 2009
  • DOI: 10.1371/journal.pbio.1000038

About the Authors

Morris E Feldman, Beth Apsel, Zachary A Knight, Kevan M Shokat
Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America
Aino Uotila, Robbie Loewith
Department of Molecular Biology, University of Geneva, Switzerland
Davide Ruggero
School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States of America

Corresponding Author

Email: shokat@cmp.ucsf.edu

Competing Interests

MEF, BA, ZAK, and KMS are inventors on patent applications owned by UCSF related to PP242 and licensed to Intellikine. ZAK and KMS are consultants to Intellikine.

Author Contributions

MEF, AU, RL, ZAK, DR, and KMS conceived and designed the experiments. MEF, BA, and AU performed the experiments. MEF, BA, AU, and KMS analyzed the data. BA, RL, ZAK, DR, and KMS contributed reagents/materials/analysis tools. MEF, BA, ZAK, DR, and KMS wrote the paper.